Why the study?
Do other oral antithrombotic agents improve primary prevention of embolic stroke in patients with atrial fibrillation compared to warfarin?
Population
Patients with atrial fibrillation
Comparison
Other oral antithrombotic agents vs Warfarin (target INR 2.5, range 2.0 to 3.0)
Design
Review
Authors
Loading...
Warfarin limitations in AF highlight need for alternatives; leaves open whether newer agents improve embolic stroke prevention.
Do other oral antithrombotic agents improve primary prevention of embolic stroke in patients with atrial fibrillation compared to warfarin?
This article discusses the limitations of warfarin for stroke prevention in atrial fibrillation and the clinical need for newer oral antithrombotic agents.
Zoppo et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: